Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APSNYSE:MBXNYSEARCA:SCYBNASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.79-24.8%C$2.62C$1.73▼C$37.20C$77.07M1.364,338 shs56,409 shsMBXMBX Biosciences$10.10-3.8%$10.55$4.81▼$27.50$337.58MN/A249,609 shs265,757 shsSCYBSchwab High Yield Bond ETF$26.17-0.1%$25.93$24.73▼$26.79$1.11B0.33372,559 shs377,121 shsTHTarget Hospitality$6.98-0.1%$6.96$4.00▼$11.10$683.63M1.85556,035 shs518,594 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences0.00%-0.83%+0.85%-56.41%-93.60%MBXMBX Biosciences+1.25%-7.57%-5.91%+24.70%+1,049,999,900.00%SCYBSchwab High Yield Bond ETF+0.31%+0.31%+0.23%+0.27%+1.69%THTarget Hospitality+1.60%+0.72%-1.55%+19.49%-10.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.031 of 5 stars3.50.00.00.00.03.30.6SCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/AN/AN/ATHTarget Hospitality1.7942 of 5 stars3.41.00.00.01.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 4.00Strong BuyN/AN/AMBXMBX Biosciences 3.00Buy$37.50271.29% UpsideSCYBSchwab High Yield Bond ETF 0.00N/AN/AN/ATHTarget Hospitality 2.75Moderate Buy$11.2561.17% UpsideCurrent Analyst Ratings BreakdownLatest MBX, TH, APS, and SCYB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025MBXMBX BiosciencesCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.004/10/2025MBXMBX BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00 ➝ $44.004/10/2025MBXMBX BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Outperform$38.003/31/2025THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$5.00 ➝ $7.50(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.12 per share1.60C($0.92) per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ASCYBSchwab High Yield Bond ETFN/AN/AN/AN/AN/AN/ATHTarget Hospitality$386.27M1.80$1.51 per share4.63$4.26 per share1.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$5.02N/A∞N/AN/A1,017.48%-136.29%N/AMBXMBX BiosciencesN/AN/A0.00N/AN/AN/AN/AN/AN/ASCYBSchwab High Yield Bond ETFN/AN/A60.28∞N/AN/AN/AN/AN/ATHTarget Hospitality$71.26M$0.4316.2319.39N/A12.71%11.34%6.94%8/6/2025 (Estimated)Latest MBX, TH, APS, and SCYB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025THTarget Hospitality-$0.02-$0.05-$0.03-$0.07$65.37 million$69.90 million3/26/2025Q4 2024THTarget Hospitality$0.06$0.12+$0.06$0.12$80.10 million$83.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ASCYBSchwab High Yield Bond ETF$1.857.07%N/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-117.371.055.41MBXMBX BiosciencesN/AN/AN/ASCYBSchwab High Yield Bond ETFN/AN/AN/ATHTarget Hospitality0.101.971.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences15.10%MBXMBX BiosciencesN/ASCYBSchwab High Yield Bond ETFN/ATHTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%MBXMBX Biosciences52.19%SCYBSchwab High Yield Bond ETFN/ATHTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3143.06 millionN/ANot OptionableMBXMBX Biosciences3633.42 millionN/AN/ASCYBSchwab High Yield Bond ETFN/A42.40 millionN/ANot OptionableTHTarget Hospitality82099.36 million31.80 millionNot OptionableMBX, TH, APS, and SCYB HeadlinesRecent News About These Companies50,000 Shares in Target Hospitality Corp. (NASDAQ:TH) Acquired by Fortitude Advisory Group L.L.C.June 17 at 5:20 AM | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded by Wall Street Zen to "Hold" RatingJune 15 at 4:13 AM | americanbankingnews.comBank of America Corp DE Sells 99,159 Shares of Target Hospitality Corp. (NASDAQ:TH)June 14 at 3:11 AM | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded at Wall Street ZenJune 14 at 2:04 AM | marketbeat.comTwo Sigma Investments LP Has $1.25 Million Holdings in Target Hospitality Corp. (NASDAQ:TH)June 5, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 78,926 Shares of Target Hospitality Corp. (NASDAQ:TH)June 4, 2025 | marketbeat.comTH Q1 Earnings Call: Revenue Miss and Government Contract Shifts Shape 2025 OutlookMay 30, 2025 | msn.comTarget Hospitality (NASDAQ:TH) Lowered to "Sell" Rating by Wall Street ZenMay 26, 2025 | marketbeat.comQ2 EPS Estimate for Target Hospitality Lowered by AnalystMay 24, 2025 | marketbeat.comAnalysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)May 22, 2025 | theglobeandmail.comTarget Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing VehicleMay 21, 2025 | prnewswire.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comTarget Hospitality Corp. (TH) Q1 2025 Earnings Call TranscriptMay 19, 2025 | seekingalpha.comTarget Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsMay 19, 2025 | msn.comTarget Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 19, 2025 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Tops Revenue EstimatesMay 19, 2025 | zacks.comTarget Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth PipelineMay 19, 2025 | prnewswire.comDimensional Fund Advisors LP Acquires 161,036 Shares of Target Hospitality Corp. (NASDAQ:TH)May 17, 2025 | marketbeat.comInsights into Target Hospitality's Upcoming EarningsMay 16, 2025 | benzinga.comHere's What to Know Ahead of Target Hospitality's Q1 EarningsMay 15, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyMBX, TH, APS, and SCYB Company DescriptionsAptose Biosciences TSE:APSC$1.79 -0.59 (-24.79%) As of 03:59 PM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.MBX Biosciences NYSE:MBX$10.10 -0.40 (-3.81%) Closing price 04:00 PM EasternExtended Trading$10.66 +0.56 (+5.50%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Schwab High Yield Bond ETF NYSEARCA:SCYB$26.17 -0.02 (-0.08%) Closing price 04:10 PM EasternExtended Trading$26.24 +0.06 (+0.25%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Schwab High Yield Bond ETF (SCYB) is an exchange-traded fund that mostly invests in high yield fixed income. The fund tracks an index of USD-denominated high-yield, US corporate bonds, selected and weighted based on market value. SCYB was launched on Jul 11, 2023 and is managed by Charles Schwab.Target Hospitality NASDAQ:TH$6.98 -0.01 (-0.14%) Closing price 04:00 PM EasternExtended Trading$6.98 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
